The study drug is a potential new treatment for Adult-Onset Muscular (Myotonic) Dystrophy Type 1 (DM1).
Degenerative myopathies, including adult-onset myotonic dystrophy type 1 (DM1), cause a range of debilitating symptoms such as muscle weakness, stiffness, and difficulty relaxing muscles after use. DM1 can also lead to fatigue, difficulty swallowing, and heart problems, significantly impacting people’s lives. Current treatments may not be sufficient, highlighting the need for new options.
This study is evaluating a potential new treatment for these symptoms. It will assess the safety, tolerability, and how the investigational medication works in healthy volunteers. This initial phase is crucial before testing the treatment in patients with these conditions.
By participating, you will contribute to research that could improve future treatments and make a positive impact on individuals and families affected by these diseases.
Call us on 1300 491 746 to discuss your eligibility today!